Is Karyopharm Therapeutics Inc. (KPTI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 120.9% / 30% | 67.6% / 30% | 19.1% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 120.9% / 33% | 67.6% / 33% | 19.1% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 118.3% / 33% | 66.1% / 33% | 18.7% / 33% | N/A | ✗ NOT HALAL |
| S&P | 120.9% / 33% | 67.6% / 33% | 19.1% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 118.3% / 33% | 66.1% / 33% | 18.7% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 9.9% | |
| Operating Margin | -52.4% | |
| Net Margin | -134.2% | |
| Return on Assets (ROA) | -41.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$75M |
| Free Cash Flow | -$75M |
| Total Debt | $234M |
| Current Ratio | 1.1 |
| Total Assets | $108M |
Price & Trading
| Last Close | $5.57 |
| 50-Day MA | $7.68 |
| 200-Day MA | $6.24 |
| Avg Volume | 598K |
| Beta | 0.2 |
|
52-Week Range
$3.51
| |
About Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Karyopharm Therapeutics Inc. (KPTI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Karyopharm Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Karyopharm Therapeutics Inc.'s debt ratio?
Karyopharm Therapeutics Inc.'s debt ratio is 120.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 118.3%.
What are Karyopharm Therapeutics Inc.'s key financial metrics?
Karyopharm Therapeutics Inc. has a market capitalization of $124M, and revenue of $146M. The company maintains a gross margin of 9.9% and a net margin of -134.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.